PHIA.AS Philips (EURONEXT) -2.33% 26 Jan 2026: earnings 28 Jan to move stock
PHIA.AS stock opened a short selling bias today after finishing at EUR 24.76, down 2.33% on 26 Jan 2026 as investors price in upcoming results. Koninklijke Philips N.V. (PHIA.AS) reports earnings on 28 Jan 2026, and this release is the key near-term catalyst for traders and long-term holders on EURONEXT in Europe. Market attention will focus on margins, free cash flow, and any update to the company’s 2026 growth outlook. We review the earnings setup, valuation, and what the Meyka AI model projects ahead.
PHIA.AS stock: Earnings setup and calendar
Koninklijke Philips N.V. will publish results on 28 Jan 2026 and the report is the main driver for PHIA.AS stock this week. Investors will watch reported EPS of EUR 0.16 (trailing) and how management addresses growth assumptions, given recent guidance commentary and SpectraWAVE acquisition activity. Expect commentary on product backlog, service revenue, and any cash-flow timing that could affect near-term free cash flow and the dividend outlook.
PHIA.AS stock: Recent price action and technicals
PHIA.AS closed at EUR 24.76, with a day range EUR 24.61–24.88 and volume 844,405 shares. The 50-day average is EUR 23.84 and the 200-day average is EUR 22.78, supporting a medium-term uptrend. Short-term indicators show overbought signals (RSI 73.53, MFI 87.44) so volatility around the earnings print is likely. Traders should note ATR 0.47 and Bollinger upper band EUR 25.15 for intraday risk limits.
PHIA.AS stock: Fundamentals and valuation snapshot
On fundamentals PHIA.AS shows a market cap near EUR 23.61 billion, trailing P/E of 155.25 (EPS EUR 0.16) and price-to-sales 1.33. Return on equity is low at 1.48% and net margin is 0.93%, both well below typical Healthcare peers. Debt-to-equity sits near 0.79 and interest coverage around 4.01, underlining leverage sensitivity. Compared with the sector average P/E 34.72, Philips trades at a significant premium that needs earnings growth or multiple expansion to justify the current price.
PHIA.AS stock: Meyka AI grade and forecast
Meyka AI rates PHIA.AS with a score of 61.38 out of 100 (Grade B — HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of EUR 25.07 and a yearly target of EUR 21.64. Relative to the current price EUR 24.76, the monthly forecast implies +1.25% upside and the yearly forecast implies -12.60% downside. Forecasts are model-based projections and not guarantees. Meyka AI, an AI-powered market analysis platform, highlights earnings as the decisive near-term input to revise these projections.
PHIA.AS stock: Risks, catalysts and sector context
Key upside catalysts are better-than-expected service revenues, margin improvement in Diagnosis & Treatment, and successful integration of recent deals. Key risks include surgical recall or warranty costs, slower hospital capital spending, and leverage strain if free cash flow weakens. The Healthcare sector in Europe has an average P/E of 34.72 and higher ROE than Philips, so PHIA.AS performance will track sector resilience, device replacement cycles, and AI-enabled diagnostic adoption.
PHIA.AS stock: Trading strategy and price targets
For traders, use earnings as a binary event: a beat could push price toward the short-term resistance at EUR 25.15 (Bollinger upper) and EUR 27.63 (52-week high); a miss could test support at EUR 22.78 (200-day MA) and the year low EUR 18.90. Reasonable price targets: a conservative 12-month target EUR 21.50 (implied downside ~-13.11%) and a bullish scenario target EUR 28.00 (implied upside ~+13.14%). Size positions to reflect earnings volatility and sector exposure.
Final Thoughts
PHIA.AS stock trades at EUR 24.76 ahead of results on 28 Jan 2026, with investors split between operational recovery and valuation risk. Short-term momentum is tight: the 50/200-day averages support the trend, but overbought technicals warn of a volatile print. Meyka AI’s forecast model projects EUR 25.07 in one month (+1.25% vs current price) and EUR 21.64 in one year (-12.60% vs current price). Those figures show a market that prices limited upside without a clean earnings beat and clearer cash-flow improvement. Our Meyka AI grade (Score 61.38/100, Grade B — HOLD) reflects mixed fundamentals, modest cash-generation and sector pressure. For investors, a cautious stance until Philips reports is sensible: consider smaller, time-limited positions or hedged exposure if you want participation ahead of the print. Forecasts are model-based projections and not guarantees—use them alongside company disclosures and analyst updates.
FAQs
When does Koninklijke Philips report and how could it affect PHIA.AS stock?
Philips reports earnings on 28 Jan 2026. A revenue or margin beat could lift PHIA.AS stock above EUR 25.15, while weaker free cash flow or guidance may push it toward the 200-day average near EUR 22.78. Expect volatility on the print.
What is Meyka AI’s near-term forecast for PHIA.AS stock?
Meyka AI’s model projects EUR 25.07 in one month for PHIA.AS stock, implying +1.25% upside versus the current EUR 24.76. Models are projections and not guaranteed outcomes.
How does Philips’ valuation compare with the Healthcare sector for PHIA.AS stock?
PHIA.AS trades at a trailing P/E of 155.25, far above the sector average P/E 34.72, reflecting low current earnings and the market pricing for future recovery. That premium increases event risk around earnings.
What are the main risks investors should watch for PHIA.AS stock?
Key risks are disappointing margins, weaker hospital capital spending, integration costs from acquisitions, and strained free cash flow that could pressure the dividend. Any negative surprise would likely increase downside near-term.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
